The Plasma Fractionation Market is projected to reach $46.9 billion by 2029, at a CAGR of 7.1% from 2022 to 2029. Plasma is a blood component derived from whole blood and used for various therapeutic and medical applications. The plasma is isolated using a method named plasma fractionation. This process leads to the fractionation of various plasma derivatives, such as albumin and immunoglobulins. These products have therapeutic effects and are employed in treating various blood-related disorders. The growth of this market is driven by the increasing prevalence of chronic diseases across all age groups, the growing use of immunoglobulins in various therapeutic areas, and the expansion of plasma collection centers. The growing prevalence of blood & respiratory disorders is expected to offer market growth opportunities. However, the high prices of plasma products and the increasing use of recombinant alternatives restrain the growth.
Impact of COVID-19 on the Plasma Fractionation Market
The current treatment for COVID-19 caused by the novel coronavirus SARS-CoV-2 has been largely limited to general supportive care, with the provision of critical care as no approved therapies are available. Many countries are adopting plasma therapy to treat COVID-19. Convalescent plasma treatment involves injecting the patient with the convalescent sera of people who have recently recovered from the COVID-19 infection. The serum of COVID-19-cured individuals has virus-neutralizing antibodies that can act as a passive antibody therapy. It is called the convalescent sera of COVID-19. These convalescent sera can be collected in two ways: (i) using routine blood withdrawal followed by centrifuge technique and (ii) using an apheresis machine/cell separator machine. As plasma treatment had positive effects on patients, various initiatives were undertaken by companies and government organizations to expand the use of plasma during the pandemic. For instance:
Such initiatives to develop plasma-based COVID-19 therapies are expected to create growth opportunities for the stakeholders in this market in the coming years.
.webp "Plasma Fractionation Market")
Click here to: Get Free Sample Copy of this report
Key Findings of the Global Plasma Fractionation Market Study:
Based on Product Type, the Immunoglobulins Segment is Expected to Account for the Largest Share
Based on product type, in 2022, the immunoglobulins segment is expected to account for the largest share of the plasma fractionation market. The large market share of this segment is attributed to the wide commercial availability of plasma-derived immunoglobulins compared to other plasma-derived products and the growing use of immunoglobulins, particularly for treating people with primary immune deficiencies or chronic inflammatory demyelinating polyneuropathy.
Based on Application, the Neurology Application Segment is Expected to Account for the Largest Share
Based on application, in 2022, the neurology segment is expected to account for the largest share of the plasma fractionation market. The large market share of this segment is attributed to factors such as the growing prevalence of neurological disorders and the wide use of plasma-derived products for their treatment.
Based on End User, the Hospitals & Clinics Segment is Expected to Account for the Largest Share
Based on end user, in 2022, the hospitals & clinics segment is expected to account for the largest share of the plasma fractionation market. The growing use of plasma-based products in multiple therapies, the growing number of hospitals, and the rising healthcare expenditure are some of the major factors driving the growth of this segment.
Asia Pacific: To be the Fastest Growing Market in 2022
Based on geography, in 2022, North America is expected to account for the largest share of the global plasma fractionation market. However, Asia-Pacific is slated to register the highest CAGR during the forecast period. The growth in the market in Asia-Pacific is driven by collaborations between the countries for establishing plasma fractionation facilities, awareness programs for an increase in the use of plasma and its fractionation, the surge in various medical conditions, such as the increasing prevalence of hemophilia among countries such as China and India that require the use of plasma fractionation products and the increasing geriatric population in the Asia-Pacific region.
Key Players
The report includes a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the last three years. The key players profiled in the global plasma fractionation market are CSL Limited (Australia), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A. (Italy), Takeda Pharmaceutical Company Limited (Japan), China Biologic Products Holdings, Inc. (China), Bio Products Laboratory Limited (BPL) (U.K.), Intas Pharmaceuticals Ltd. (India), LFB Group (France), ADMA Biologics, Inc. (U.S.), SK Plasma (South Korea), and GC Biopharma Corp. (South Korea).
Scope of the Report:
Plasma Fractionation Market, by Product
Plasma Fractionation Market, by Application
Plasma Fractionation Market, by End User
Plasma Fractionation Market, by Geography
Key questions answered in the report:
The global plasma fractionation market report covers the market size & forecasts the various plasma fractionated products used in the healthcare sector. The plasma fractionation market studied in this report involves the value analysis of various segments and sub-segments of plasma fractionated products at the regional and country levels.
The global plasma fractionation market is projected to reach $46.9 billion by 2029, at a CAGR of 7.1% during the forecast period.
In 2022, the immunoglobulins segment is expected to account for the largest share. The same segment is expected to register the highest CAGR over the forecast period.
In 2022, the neurology segment is expected to account for the largest share of the market. Moreover, this segment is expected to grow with the highest CAGR during the forecast period.
The hospitals & clinics segment is projected to register the highest CAGR during the forecast period owing to the growing population of visiting hospitals and clinics for their disease treatments.
The growth of this market is driven by the increasing prevalence of chronic diseases across all age groups, the growing use of immunoglobulins in various therapeutic areas, and the expansion of plasma collection centers. Furthermore, the growing prevalence of blood & respiratory disorders offers a significant growth opportunity for the market players during the forecast period.
The key players operating in the global plasma fractionation market are CSL Limited (Australia), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A. (Italy), Takeda Pharmaceutical Company Limited (Japan), China Biologic Products Holdings, Inc. (China), Bio Products Laboratory Limited (BPL) (U.K.), Intas Pharmaceuticals Ltd. (India), LFB Group (France), ADMA Biologics, Inc. (U.S.), SK Plasma (South Korea), and GC Biopharma Corp. (South Korea).
Emerging economies such as China and India in Asia are projected to offer significant growth opportunities for the vendors in this market due to the increasing adoption of plasma-derived products for the treatment of various diseases and COVID-19.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. Increasing Prevalence of Chronic Diseases Across All Age Groups
4.2.2. Growing Use of Immunoglobulins in Various Therapeutic Areas
4.2.3. Expansion of Plasma Collection Centers
4.3. Restraints
4.3.1. High Prices of Plasma Products
4.3.2. Increasing Use of Recombinant Alternatives
4.4. Opportunities
4.4.1. Growing Prevalence of Blood & Respiratory Disorders
4.5. Challenges
4.5.1. Stringent Regulations in Developing Countries
4.6. The Impact of COVID-19 on the Plasma Fractionation Market
5. Plasma Fractionation Market, by Product
5.1. Introduction
5.2. Immunoglobulins
5.2.1. Intravenous Immunoglobulins (IVIg)
5.2.2. Subcutaneous Immunoglobulins (SCIg)
5.2.3. Intramuscular Immunoglobulins (IMIg)
5.3. Albumin
5.4. Protease Inhibitors
5.5. Coagulation Factors
5.6. Other Products
6. Plasma Fractionation Market, by Application
6.1. Introduction
6.2. Neurology
6.3. Immunology
6.4. Hematology
6.5. Critical Care
6.6. Hematology-Oncology
6.7. Rheumatology & Orthopedics
6.8. Other Applications
7. Plasma Fractionation Market, by End User
7.1. Introduction
7.2. Hospitals & Clinics
7.3. Clinical Research Laboratories
7.4. Academic & Research Institutes
8. Plasma Fractionation Market, by Geography
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe (RoE)
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. Australia
8.4.4. India
8.4.5. Indonesia
8.4.6. Vietnam
8.4.7. Thailand
8.4.8. Malaysia
8.4.9. Rest of Asia Pacific (RoAPAC)
8.5. Latin America
8.5.1. Brazil
8.5.2. Mexico
8.5.3. Colombia
8.5.4. Peru
8.5.5. Rest of Latin America (RoLATM)
8.6. Middle East & Africa
8.6.1. South Africa
8.6.2. Rest of Middle East & Africa (RoMEA)
9. Competitive Landscape
9.1. Introduction
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.3.1. Competitive Benchmarking, by Product
9.4. Market Share Analysis (2021)
9.4.1. Global Plasma Fractionation/Products Market Share Analysis, by Company (2021)
9.4.1.1. CSL Limited
9.4.1.2. Takeda Pharmaceutical Company Limited
9.4.1.3. Grifols, S.A.
9.4.2. Global Immunoglobulins Market Share Analysis, by Company, 2021
9.4.3. Global Albumin Market Share Analysis, by Company, 2021
9.4.4. Global Protease Inhibitors Market Share Analysis, by Company, 2021
9.4.5. Global Coagulation Factors Market Share Analysis, by Company, 2021
10. Company Profiles
10.1. CSL Limited
10.2. Grifols, S.A.
10.3. Octapharma AG
10.4. Kedrion S.p.A.
10.5. Takeda Pharmaceutical Company Limited
10.6. China Biologic Products Holdings, Inc.
10.7. Bio Products Laboratory (BPL) Ltd
10.8. Intas Pharmaceuticals Ltd.
10.9. LFB Group
10.10. ADMA Biologics, Inc.
10.11. SK Plasma
10.12. GC Biopharma Corp.
11. Appendix
11.1. Questionnaire
11.2. Available Customization
List of Tables
Table 1 Global Plasma Fractionation Market: Impact Analysis of Market Drivers (2022–2029)
Table 2 Number of Persons Aged 65 Years or Over, by Region (2019 Vs. 2030)
Table 3 U.S. and Europe: Plasma Collection Centers and Throughput, 2015–2019
Table 4 Recently Established Plasma Centers (2018–2022)
Table 5 Global Plasma Fractionation Market: Impact Analysis of Market Restraints (2022–2029)
Table 6 Plasmapheresis Parameters
Table 7 Global Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 8 Key Players Offering Immunoglobulins
Table 9 Global Plasma-derived Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 10 Global Plasma-derived Immunoglobulins Market Size, by Country/Region, 2020–2029 (USD Million)
Table 11 Global Plasma-derived Immunoglobulins Market Volume, by Country/Region, 2020–2029 (100 Kg)
Table 12 Comparison of IVIg and SCIg
Table 13 Some Commercially Available IVIg Products and their Properties
Table 14 Global Plasma-derived Intravenous Immunoglobulins Market Size, by Country/Region, 2020–2029 (USD Million)
Table 15 Global Intravenous Immunoglobulins Volume, by Country/Region, 2020–2029 (100 Kg)
Table 16 Some Commercially Available SCIg Products and their Properties
Table 17 Global Plasma-derived Subcutaneous Immunoglobulins Market Size, by Country/Region, 2020–2029 (USD Million)
Table 18 Global Subcutaneous Immunoglobulins Market Volume, by Country/Region, 2020–2029 (100 Kg)
Table 19 Global Intramuscular Immunoglobulins Market Size, by Country/Region, 2020–2029 (USD Million)
Table 20 Global Intramuscular Immunoglobulins Market Volume, by Country/Region, 2020–2029 (100 Kg)
Table 21 Key Players Offering Albumin
Table 22 Global Plasma-derived Albumin Market Size, by Country/Region, 2020–2029 (USD Million)
Table 23 Global Plasma-derived Albumin Market Volume, by Country/Region, 2020–2029(100 Kg)
Table 24 Key Players offering Protease Inhibitors
Table 25 Global Plasma-derived Protease Inhibitors Market Size, by Country/Region, 2020–2029 (USD Million)
Table 26 Global Plasma-derived Protease Inhibitors Market Volume, by Country/Region, 2020–2029 (Hundred Vials of 10 ml)
Table 27 Key Players Offering Coagulation Factors
Table 28 Global Plasma-derived Coagulation Factors Market Size, by Country/Region, 2020–2029 (USD Million)
Table 29 Global Plasma-derived Coagulation Factors Market Volume, by Country/Region, 2020–2029 (Million)
Table 30 Global Other Plasma-derived Products Market Size, by Country/Region, 2020–2029 (USD Million)
Table 31 Global Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 32 Key Vendors Offering Plasma-derived Products for Neurological Applications
Table 33 Global Plasma Fractionation Market Size for Neurology, by Country/Region, 2020–2029 (USD Million)
Table 34 Key Players Offering Products for Immunology Applications
Table 35 Global Plasma Fractionation Market Size for Immunology, by Country/Region, 2020–2029 (USD Million)
Table 36 Key Vendors Offering Plasma-derived Products for Hematology
Table 37 Global Plasma Fractionation Market Size for Hematology, by Country/Region, 2020–2029 (USD Million)
Table 38 Key Vendors Offering Plasma-derived Products for Critical Care
Table 39 Global Plasma Fractionation Market Size for Critical Care, by Country/Region, 2020–2029 (USD Million)
Table 40 Global Plasma Fractionation Market Size for Hematology-Oncology, by Country/Region, 2020–2029 (USD Million)
Table 41 Global Plasma Fractionation Market Size for Rheumatology and Orthopedics, by Country/Region, 2020–2029 (USD Million)
Table 42 Global Plasma Fractionation Market Size for Other Applications, by Country/Region, 2020–2029 (USD Million)
Table 43 Global Plasma Fractionation Market Size, by End User, 2020-2029 (USD Million)
Table 44 Global Plasma Fractionation Market Size for Hospitals & Clinics, by Country/Region, 2020–2029 (USD Million)
Table 45 Few Plasma Products Under Clinical Trials, 2016–2020
Table 46 Global Plasma Fractionation Market Size for Clinical Research Laboratories, by Country/Region, 2020–2029 (USD Million)
Table 47 Global Plasma Fractionation Market Size for Academic & Research Institutes, by Country/Region, 2020–2029 (USD Million)
Table 48 Global Plasma Fractionation Market Size, by Country/Region, 2020–2029 (USD Million)
Table 49 North America: Plasma Fractionation Market Size, by Country, 2020–2029 (USD Million)
Table 50 North America: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 51 North America: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 52 North America: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 53 North America: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 54 U.S.: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 55 U.S.: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 56 U.S.: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 57 U.S.: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 58 Canada: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 59 Canada: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 60 Canada: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 61 Canada: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 62 Europe: Plasma Fractionation Market Size, by Country, 2020–2029 (USD Million)
Table 63 Europe: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 64 Europe: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 65 Europe: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 66 Europe: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 67 Germany: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 68 Germany: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 69 Germany: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 70 Germany: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 71 France: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 72 France: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 73 France: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 74 France: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 75 U.K.: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 76 U.K.: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 77 U.K.: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 78 U.K.: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 79 Italy: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 80 Italy: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 81 Italy: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 82 Italy: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 83 Spain: Hemoderivatives Production, 2013–2021
Table 84 Spain: Self-sufficiency for Plasma-derived Products
Table 85 Spain: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 86 Spain: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 87 Spain: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 88 Spain: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 89 Roe: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 90 Roe: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 91 Roe: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 92 Roe: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 93 Asia-Pacific: Plasma Fractionation Market Size, by Country, 2020–2029 (USD Million)
Table 94 Asia-Pacific: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 95 Asia-Pacific: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 96 Asia-Pacific: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 97 Asia-Pacific: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 98 China: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 99 China: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 100 China: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 101 China: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 102 Japan: Domestic Production and Import of PDMP
Table 103 Japan: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 104 Japan: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 105 Japan: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 106 Japan: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 107 Australia: Blood and Blood Products Purchased by Product Category 2016–2017 to 2020–2021
Table 108 Australia: Current Products and Expected Transitioned Products by National Fractionation Agreement
Table 109 Australia: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 110 Australia: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 111 Australia: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 112 Australia: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 113 India: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 114 India: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 115 India: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 116 India: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 117 Indonesia: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 118 Indonesia: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 119 Indonesia: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 120 Indonesia: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 121 Vietnam: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 122 Vietnam: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 123 Vietnam: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 124 Vietnam: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 125 Thailand: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 126 Thailand: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 127 Thailand: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 128 Thailand: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 129 Malaysia: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 130 Malaysia: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 131 Malaysia: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 132 Malaysia: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 133 RoAPAC: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 134 RoAPAC: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 135 RoAPAC: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 136 RoAPAC: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 137 Latin America: Plasma Fractionation Market Size, by Country/Region, 2020–2029 (USD Million)
Table 138 Latin America: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 139 Latin America: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 140 Latin America: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 141 Latin America: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 142 Brazil: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 143 Brazil: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 144 Brazil: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 145 Brazil: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 146 Mexico: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 147 Mexico: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 148 Mexico: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 149 Mexico: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 150 Colombia: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 151 Colombia: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 152 Colombia: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 153 Colombia: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 154 Peru: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 155 Peru: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 156 Peru: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 157 Peru: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 158 Rest of Latin America: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 159 Rest of Latin America: Immunoglobulins Market Size, by Type, 2020–2029 (USD Million)
Table 160 Rest of Latin America: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 161 Rest of Latin America: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 162 Middle East & Africa: Plasma Fractionation Market Size, by Country, 2020–2029 (USD Million)
Table 163 Middle East & Africa: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 164 Middle East & Africa: Plasma Fractionation Market Size for Immunoglobulins, by Type, 2020–2029 (USD Million)
Table 165 Middle East & Africa: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 166 Middle East & Africa: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 167 South Africa: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 168 South Africa: Plasm Fractionation Market Size for Immunoglobulins, by Type, 2020–2029 (USD Million)
Table 169 South Africa: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 170 South Africa: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 171 Rest of Middle East & Africa: Population With Bleeding Disorder in 2020
Table 172 Rest of Middle East and Africa: Plasma Fractionation Market Size, by Product, 2020–2029 (USD Million)
Table 173 Rest of Middle East and Africa: Plasma Fractionation Market Size for Immunoglobulins, by Type, 2020–2029 USD Million)
Table 174 Rest of Middle East and Africa: Plasma Fractionation Market Size, by Application, 2020–2029 (USD Million)
Table 175 Rest of Middle East and Africa: Plasma Fractionation Market Size, by End User, 2020–2029 (USD Million)
Table 176 Recent Developments, by Company, 2020–2022
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Global Plasma Fractionation Market, by Product, 2022 Vs. 2029 (USD Million)
Figure 8 Global Plasma Fractionation Market, by Application, 2022 Vs. 2029 (USD Million)
Figure 9 Global Plasma Fractionation Market, by End User, 2022 Vs. 2029 (USD Million)
Figure 10 Global Plasma Fractionation Market, by Geography
Figure 11 Market Dynamics
Figure 12 Number of Genes Identified Within Born Immunity Errors (2015–2019)
Figure 13 COVID-19 Associated Hospitalizations (As of 6th June 2020)
Figure 14 IVIg/SCIg Usage, by Country, 2005 Vs. 2014 Vs. 2018 (Kg/Million Population)
Figure 15 Comparison Between the Cost Structures of the Plasma Industry and the Non-plasma Pharmaceutical Industry
Figure 16 Global Plasma Fractionation Market Size, by Product, 2022 Vs. 2029 (USD Million)
Figure 17 Global Sales of C1 Esterase Inhibitor (C1-INH) for Haematology Between 2010 and 2016 (USD Million)
Figure 18 Global Plasma Fractionation Market Size, by Application, 2022 Vs. 2029 (USD Million)
Figure 19 Percent Share of Polyvalent IGg in Plasma Proteins Market
Figure 20 Global Number of Orthopedic Surgeries, 2010–2020 (In Million)
Figure 21 Global Plasma Fractionation Market Size, by End User, 2022 Vs. 2029 (USD Million)
Figure 22 Global Plasma Fractionation Market Size, by Region, 2022 Vs. 2029 (USD Million)
Figure 23 North America: Plasma Fractionation Market Snapshot
Figure 24 U.S.: Number of Plasma Collection Centers, 2011–2020
Figure 25 Europe: Plasma Fractionation Market Snapshot
Figure 26 Italy: Plasma for Fractionation, 2007–2020
Figure 27 Asia-Pacific: Plasma Fractionation Market Snapshot
Figure 28 Latin America: Plasma Fractionation Market Snapshot
Figure 29 RoLATM: Number of Whole Blood Donations Collected From Voluntary Non-remunerated Donations, 2015–2019
Figure 30 Argentina: Number of People Suffering From Hemophilia (2018–2020)
Figure 31 Middle East & Africa: Plasma Fractionation Market Snapshot
Figure 32 South Africa: Number of Whole Blood Donations (2014–2019)
Figure 33 Algeria: Number of Voluntary Non-remunerated Whole Blood Donations
Figure 34 Key Growth Strategies Adopted by Leading Players, 2020–2022
Figure 35 Plasma Fractionation: Competitive Benchmarking Based on Product
Figure 36 CSL Limited: Financial Overview (2021)
Figure 37 Grifols, S.A.: Financial Overview (2021)
Figure 38 Octapharma AG: Financial Overview (2021)
Figure 39 Kedrion S.p.A.: Financial Overview (2021)
Figure 40 Takeda Pharmaceutical Company Limited: Financial Overview (2021)
Figure 41 China Biologic Products Holdings, Inc.: Financial Overview (2020)
Figure 42 Intas Pharmaceuticals Ltd: Financial Overview (2019)
Figure 43 ADMA Biologics, Inc.: Financial Overview (2021)
Figure 44 GC Biopharma Corp: Financial Overview (2021).
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Nov-2021
Published Date: Jan-2023
Published Date: Aug-2017
Published Date: Jul-2022
